Evolution of the treatment of chronic myeloid leukemia and dynamics correlation of quality of life in patients undergone the implementation in practice of tyrosine kinase inhibitors


The article is devoted to review of current approaches to the pathogenesis, clinical course, diagnosis and evolution of the treatment of chronic myeloid leukemia from preparations of arsenic to tyrosine kinase inhibitors. In this article the modern concept of quality of life and types of questionnaires which are used to study quality of life in cancer patients has been described. The possibility of achieving a good health-related quality of life in patients with chronic myeloid leukemia after the implementation in practice of tyrosine kinase inhibitors has been considered.

Full Text

Эволюция терапии хронического миелолейкоза и взаимосвязь динамики качества жизни больных с внедрением в практику ингибиторов тирозинкиназ

About the authors

N V Liseeva

N V Liseeva


  1. Nowell P.C., Hungerford D.A. // A minute chromosome in human chronic granulocytic leukemia // Jonfl of the National Cancer Institute, 1960, № 25, P. 85-109.
  2. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M. et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene // Science. – 1986. – V.233, №4760. – P.212–214
  3. Lugo T.G., Pendergast A.M., Muller A.J. et al. // Tyrosine kinase activity and transformation potency of bcr-abl oncogene products // Science, 1990, V.247, № 4946, P.1079–1082
  4. Deininger М, W., Vieira S., Mendiola R. et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia // Cancer Res. - 2000. - Vol. 60. - P. 2049-2055.
  5. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K-562 leukemia cells unmasks associated tyrosine kinase activity. // Cell. -1984. -Vol. 37.- PP. 1035-1042
  6. Holyoake D.T. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.// Br. J. Haematol. -2001 -Vol.113.-PP. 11-23.
  7. Babicka L., Zemanova Z., Pavlistova L. et al. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2006;168(1):22–9
  8. Majlis A., Smith T.L., Talpaz M. et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996;14:196–203
  9. Gordon M.Y., Goldman J.M. // Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment // Brit. J. Haematol, 1996, V.95, №1, P. 10-20.
  10. Cortes J., M.E. O’Dwyer. // Clonal evolution in chronic myelogenous leukemia. Hematol. // Oncol. Clin. N Am, 18, 2004, P. 671-684
  11. Cortes J., Kantarjian H.M., O'Brien S. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.//American Journal of Medicine.-1996.-Vol.l00.-PP.452-455. 2128-2137.
  12. Волкова М.А. и др. // Хронический миелолейкоз. // Клиническая онкогематология, 2001, стр. 247.
  13. Haddow A, Timmis G.M. // Lancet. // 1953, Vol. 264, P. 207-208.
  14. Kyle R.A., Schwartz R.S., Oliner H.L. et al. // Blood.//. 1961.-Vol. 18.-P. 497-503.
  15. Kirshner R.H., Easterly J. //Cancer.// -1971.-Vol.27.-P.1077-1080.
  16. Kantarjian H.M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update.// Blood.- 1993.-Vol.82.-PP.691-703.
  17. Хорошко Н.Д. //Современная терапия хронического миелолейкоза. // Автореф. дисерт. докт. мед.наук, 1992.
  18. Bhatia R., Munthe H., Verfaillie C.M. // Blood. // -1996.-Vol. 88. –P. 2537.
  19. Абдулкадыров К.М., Удальева В.Ю., Рукавицын О.А., Бессмельцев С.С. Альфа-интерфероны в лечении больных хроническим миелолейкозом. // Вопросы онкологии.-1999.-Т.45, №4.-С. 387-392
  20. Kantarjian H.M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update.// Blood.- 1993.-Vol.82.-PP.691-703.
  21. Wetzler М., Kantarjian Н., Kurzrock R,, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukemia, //Am. J. Med. - 1995. - Vol.99(4). - PP. 402-411
  22. Giralt S., Kantarjian H., Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era.//Semin. Hematol. - 1995.- Vol.32(2). - PP. 152-158.
  23. Hehlmann R., Heimpel H., Kolb H.J. et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 1993;11(Suppl 1):159–68
  24. Bonifazi F., de Vivo A., Rosti G. et al.; European Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074–81
  25. Абдулкадыров К.М., Удальева В.Ю., Рукавицын О.А., Бессмельцев С.С. Альфа-интерфероны в лечении больных хроническим миелолейкозом. // Вопросы онкологии.-1999.-Т.45, №4.-С. 387-392.
  26. Kantarjian HM, Talpaz M. // Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia // Semin Oncol., 1994, , № 21 (6 Suppl 14),Р. 8-13
  27. Goldman J. // Management of chronic myeloid leukemia.// Semin. Hematol. - 2003. -Vol.40.-PP. 1-103; Silver RT, Woolf SH, Hehlmann R, et al. // An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology // Blood., 1999, V. 94, P. 1517-36.
  28. Alimena G., Breccia M., Latagliata R.et al. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006;107(5):1008-13; Lahaye T., Riehm B., Berger U. et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103(8):1659-69
  29. Kantarjian H.M., Smith T.L., McCredie K.B. et al. // Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival // Blood, 1985, V.66, № 6, P. 1326-1335; Melo J.V. // The molecular biology of chronic myeloid leukaemia // Leukemia. // 1996, V.10, № 5, P.751-756
  30. Hochhaus A. // Cytogenetic and molecular mechanisms of resistance to imatinib // Semin. Hematol., 2003, V.40, № 2, Suppl 2, P.69-79.
  31. Kantarjian H., Talpaz M., Giles F. et al. // New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance // Ann. Intern. Med, 2006, V.145, №12, P. 913-923; Weisberg, E. et al. // AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. // Br. J. Cancer, 2006, 94, P.1765–1769
  32. Hehlmann R, Hochhaus A, Baccarani M // on behalf ot the European LeukemiaNet: Chronic myeloid leukaemia // Lancet, 2007, 370, P. 342-50; Apperley JF. // Part II: Management of resistance to imatinib in chronic myeloid leukaemia. // Lancet Oncol., 8, P. 1116-1129, 2007.
  33. Copland M., Hamilton A., Elrick L.J. et al. // Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary chronic myeloid leukemia but does not eliminate the quiescent fraction // Blood 2006, N107, P. 4532-9.
  34. Shah N.P. Dasatinib // Drugs of Today. // 2007, V. 43, N 1, P. 5-12.
  35. Jayson, G. C. et al. // Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. // J. Clin. Oncol, 2005, 23, P. 973–981.
  36. Новик А. А., Ионова Т. И. //Исследование качества жизни в онкогематологии. // Клиническаяонкогематология, 2008; №1, С.168-173; Рабочая книга социолога. – М.: Наука, 1976. – С.307
  37. Bowling A. Measuring Disease: a review of disease-specific quality of life measurement scales. – Open University Press: Philadelphia, 1996. 374p.
  38. Bostrom B., Sandh M., Lundberg D., Fridlund B. A comparison of pain and health-related quality of life between two groups of cancer patients with differing average levels of pain. J. Clinic. Nurs. 2003; 12: 726-735.
  39. Cherny N. Cancer pain: principles of assessment and syndromes. Principles and practice of supportive oncology; Eds. A. M. Berger, R. K. Portenoy, D. E. Weissman. NY.: Lippincott-Raven. 1998: 3-34
  40. Glise H, Hallerback B, Wiklund I. Quality of Life: a reflection of symptoms and concerns. Scand. J. Gastroenterol. 1996; 221: 14- 17.
  41. Goisis A., Gorini M., Ratti R. et al. Application of a WHO protocol on medical therapy for oncologic pain in internal medicine hospital.Tumori. 1989; 75: 470:172
  42. Cella D. Manual: Functional Assessment of Cancer Therapy (FACT). NY.: Scales.1992; Winningham M. L., Nail L. M., Burke M. B. et al. Fatigue and the cancer experience: the state of the knowledge. Oncology Nursing Forum. 1994; 21(1): 23-36
  43. Wisloff F., Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br. J. Haematol. 1997; 97: 29 37.
  44. Сёмочкин С.В., Лория С.С., Курова Е.С., Трипутень Н.З. // Качество жизни больных с хроническим миелолейкозом в фазе акселерации в процессе терапии гливеком. // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2003. Т. 2. №1. С. 84-86
  45. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003;21(11):2138-2146
  46. Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011;52(6):1017-1023



Abstract - 45


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 2013 Liseeva N.V., Liseeva N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies